Randomized, double‐blind, phase 3 study of tucatinib or placebo in combination with ado‐trastuzumab emtansine (T‐DM1) for subjects with unresectable locally‐advanced or metastatic HER2+ breast cancer (HER2CLIMB‐02). Here, ERBB2 is linked to breast cancer.